Basket cover image
15 handpicked stocks

Analyst All-Stars

Take advantage of Wall Street's collective wisdom with this portfolio of top-rated stocks. These companies have earned strong 'Buy' ratings from respected financial analysts because of their solid fundamentals and potential for market outperformance.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जून 18

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

AVGO

Broadcom Inc.

AVGO

Current price

$294.91

A semiconductor and software giant, it is consistently rated 'Buy' by analysts due to its market leadership and integral role in global technology inf...

A semiconductor and software giant, it is consistently rated 'Buy' by analysts due to its market leadership and integral role in global technology infrastructure.

MORN

Morningstar Inc.

MORN

Current price

$260.37

As a leading provider of investment insights, it earns a 'Buy' rating from analysts who value its strong brand and data services.

BGC

BGC Partners, Inc.

BGC

Current price

$9.78

This global financial services company consistently earns a 'Strong Buy' rating from analysts for its strong market position and growth outlook.

About This Group of Stocks

1

Our Expert Thinking

This collection harnesses the collective intelligence of Wall Street's most trusted analysts. By focusing on companies with strong consensus 'Buy' ratings, we're leveraging deep institutional research to identify businesses with robust fundamentals and clear paths to growth.

2

What You Need to Know

These stocks span diverse industries from technology to finance, offering built-in diversification. Each company has passed rigorous professional scrutiny of its financial health, competitive position, and management quality, creating a growth-oriented portfolio backed by expert validation.

3

Why These Stocks

Each company was selected because it earned a 'Strong Buy' or 'Buy' rating from a significant majority of analysts covering it. In a market overwhelmed with information, this expert consensus acts as a critical filter for identifying quality stocks with higher probability of outperformance.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+172.76%

Group Performance Snapshot

172.76%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 172.76% over the next year.

15 of 15

Stocks Rated Buy by Analysts

15 of 15 assets in this group are rated Buy by professional analysts.

4.5% vs 4%

Group Growth vs Bank interest

This group averaged a 4.5% return last month, beating the typical 4% bank rate.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🧠

Wall Street's Best Thinking

These stocks represent the distilled wisdom of countless hours of professional research. When top analysts agree on a company's potential, it's worth paying attention.

🔍

Professionally Vetted Winners

Feel more confident knowing these companies have passed through rigorous scrutiny. Every stock has been thoroughly analyzed for financial health, competitive positioning, and growth potential.

🌟

Hidden Gems Across Industries

Discover opportunities you might have missed. This diverse collection spans tech innovators, healthcare pioneers, and financial leaders - all backed by professional conviction.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Orphan Drug Moats: Leaders In Rare Disease

Orphan Drug Moats: Leaders In Rare Disease

The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.

View stocks
Nvidia's China Chip Pivot

Nvidia's China Chip Pivot

Nvidia is developing a new, compliant AI chip for China, aiming to recapture market share lost to U.S. export controls. This strategic pivot creates a ripple effect, potentially benefiting the entire semiconductor supply chain that supports the production and deployment of this advanced hardware.

View stocks
Navigating The Autonomous Driving Shakeout

Navigating The Autonomous Driving Shakeout

A class-action lawsuit against Tesla regarding its Full Self-Driving claims puts the company's marketing and technology under intense scrutiny. This legal challenge could boost demand for competing autonomous driving technologies, creating opportunities for companies that supply advanced sensors and software.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.